Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 5/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.51 |
| ▸ | SETD2 | Q9BYW2 | 2/20 | 0.50 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25966616 | 1.00 | NPY5R (0.53) | NPY5RMCHR1SETD2PIK3CDMAP4K4 | |
| SCHEMBL26881424 | 0.93 | NPY5R (0.47) | NPY5RMCHR1SETD2PIK3CDMAP4K4 | |
| SCHEMBL14321771 | 0.92 | NPY5R (0.61) | NPY5RMCHR1SETD2PIK3CDEPHX2 | |
| SCHEMBL14905667 | 0.90 | NPY5R (0.53) | NPY5RMCHR1SETD2NOTUMEPHX2 | |
| SCHEMBL19710460 | 0.86 | NOTUM (0.60) | NPY5RMCHR1SETD2PIK3CDMAP4K4 | |
| SCHEMBL4186891 | 0.84 | NPY5R (0.48) | NPY5RMCHR1NOTUMALOX5 | |
| SCHEMBL19702028 | 0.82 | NOTUM (0.62) | MCHR1SETD2PIK3CDMAP4K4NOTUM | |
| SCHEMBL14321789 | 0.82 | NPY5R (0.61) | NPY5RNOTUMEPHX2ALOX5 | |
| SCHEMBL26881412 | 0.80 | NPY5R (0.56) | NPY5RPIK3CDALOX5 | |
| SCHEMBL26881395 | 0.80 | NPY5R (0.56) | NPY5RPIK3CDALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| EP-4223754-A1 | COMPOUND AS AKT KINASE INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357242-A1 | COMPOUND AS AKT KINASE INHIBITOR | AKT2, MTOR, AKT1 | NPY5R 3354/4885MCHR1 4663/4885SETD2 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.